ACRS Aclaris Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACRS

Price (delayed)

$5.86

Market cap

$862.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.58

Enterprise value

$843.42M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 96
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 15

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The ...

Highlights
Aclaris Therapeutics's gross margin has increased by 33% QoQ and by 26% YoY
Aclaris Therapeutics's EPS has surged by 63% YoY but it has decreased by 3.6% QoQ
The company's net income rose by 44% YoY but it fell by 9% QoQ
The company's revenue has shrunk by 51% YoY
Aclaris Therapeutics's quick ratio has decreased by 14% QoQ and by 7% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.aclaristx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ACRS

ACRS stock price

How has the Aclaris Therapeutics stock price performed over time
Intraday
0.34%
1 week
-3.78%
1 month
6.55%
1 year
244.71%
YTD
94.68%
QTD
10.78%

Financial performance

How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$8.22M
Gross profit
$1.06M
Operating income
-$85.51M
Net income
-$75.74M
Gross margin
12.9%
Net margin
-921.5%
The company's revenue has shrunk by 51% YoY
The company's net income rose by 44% YoY but it fell by 9% QoQ
The operating income has increased by 41% YoY but it has decreased by 9% from the previous quarter
ACRS's gross profit is down by 38% YoY but it is up by 31% from the previous quarter

Price vs fundamentals

How does ACRS's price correlate with its fundamentals

Growth

What is Aclaris Therapeutics's growth rate over time

Valuation

What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
6.57
P/S
101.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
102.62
Aclaris Therapeutics's EPS has surged by 63% YoY but it has decreased by 3.6% QoQ
ACRS's P/B is 119% above its 5-year quarterly average of 3.0 and 93% above its last 4 quarters average of 3.4
ACRS's equity is down by 13% QoQ and by 5% YoY
ACRS's P/S is 105% above its 5-year quarterly average of 49.7 and 92% above its last 4 quarters average of 52.9
The company's revenue has shrunk by 51% YoY

Efficiency

How efficient is Aclaris Therapeutics business performance
Aclaris Therapeutics's return on invested capital has increased by 38% YoY but it has decreased by 10% QoQ
The ROA has increased by 38% YoY but it has decreased by 10% from the previous quarter
The company's return on equity rose by 36% YoY but it fell by 10% QoQ
Aclaris Therapeutics's return on sales has decreased by 15% YoY and by 11% QoQ

Dividends

What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRS.

Financial health

How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's quick ratio has decreased by 14% QoQ and by 7% YoY
ACRS's current ratio is down by 14% since the previous quarter and by 11% year-on-year
ACRS's debt is 100% less than its equity
ACRS's equity is down by 13% QoQ and by 5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.